Carmell Therapeutics Corporation (NASDAQ:CTCX) — Stock Price
Carmell Therapeutics Corporation (NASDAQ:CTCX) is currently trading at $0.15 USD, up 0.00% today. Over the past 52 weeks, shares have ranged between $0.15 and $0.15. This page tracks Carmell Therapeutics Corporation's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see CTCX market cap.
Carmell Therapeutics Corporation (CTCX) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Carmell Therapeutics Corporation's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Daily price history is not currently available for Carmell Therapeutics Corporation.
Carmell Therapeutics Corporation Income Statement — Revenue, Profit & Earnings by Year
Carmell Therapeutics Corporation's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Total Revenue | $50.32K | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $6.36K | $124.79K | $242.56K | — |
| Gross Profit | $43.96K | $-124.79K | $-242.56K | — |
| Research & Development | $1.05 Million | $2.50 Million | $2.20 Million | $982.84K |
| SG&A | $3.72 Million | $2.62 Million | $3.22 Million | $863.33K |
| Total Operating Expenses | $5.04 Million | $5.09 Million | $5.51 Million | $1.94 Million |
| Operating Income | $-5.00 Million | $-5.22 Million | $-5.51 Million | $-1.94 Million |
| EBITDA | $-560.66K | $-15.19 Million | $-5.25 Million | $-1.66 Million |
| EBIT | $-757.92K | $-15.32 Million | $-5.50 Million | $-1.90 Million |
| Interest Expense | $49.02K | $889.32K | $3.75 Million | $2.50 Million |
| Income Before Tax | $-10.75 Million | $-16.21 Million | $-9.05 Million | $-6.48 Million |
| Income Tax Expense | $-97.28K | $-760.16K | $391.20K | $2.54 Million |
| Net Income | $-10.37 Million | $-15.45 Million | $-9.05 Million | $-6.48 Million |
Carmell Therapeutics Corporation Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Carmell Therapeutics Corporation's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Total Assets | $1.47 Million | $63.95 Million | $1.75 Million | $1.56 Million |
| Total Current Assets | $955.55K | $62.90 Million | $605.54K | $178.70K |
| Cash & Equivalents | — | — | — | — |
| Short-term Investments | — | — | — | — |
| Net Receivables | $305.93K | $204.56K | — | — |
| Inventory | $108.70K | $0.00 | — | — |
| Property, Plant & Equipment | — | — | — | — |
| Goodwill | — | — | — | — |
| Total Liabilities | $6.19 Million | $39.20 Million | $39.54 Million | $31.13 Million |
| Total Current Liabilities | $5.88 Million | $38.50 Million | $7.30 Million | $15.80 Million |
| Long-term Debt | — | — | — | $922.00 |
| Net Debt | $481.85K | $-776.01K | $3.61 Million | $9.67 Million |
| Total Stockholder Equity | $-4.71 Million | $24.75 Million | $-37.79 Million | $-29.58 Million |
| Retained Earnings | $-68.87 Million | $-58.50 Million | $-42.38 Million | $-32.77 Million |
Carmell Therapeutics Corporation Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Carmell Therapeutics Corporation generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Operating Cash Flow | $-4.39 Million | $-8.35 Million | $-3.43 Million | $-1.18 Million |
| Capital Expenditures | $0.00 | $30.47K | $7.16K | $7.27K |
| Free Cash Flow | $-4.39 Million | $-8.38 Million | $-3.44 Million | $-1.18 Million |
| Investing Cash Flow | — | — | — | — |
| Financing Cash Flow | $2.38 Million | $11.16 Million | $3.55 Million | $1.20 Million |
| Dividends Paid | — | — | — | — |
| Stock-Based Compensation | $827.04K | $667.68K | $636.37K | $246.80K |
| Depreciation | $197.26K | $124.79K | $242.56K | $242.12K |
| Change in Cash | $-2.76 Million | $2.78 Million | $115.79K | $11.21K |
Carmell Therapeutics Corporation Earnings History — EPS Actual vs. Analyst Estimates
Track Carmell Therapeutics Corporation's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Jun 30, 2024 | -0.16 | — | — |
| Mar 31, 2024 | -0.14 | — | — |
| Sep 30, 2023 | -0.62 | — | — |
| Jun 30, 2023 | 0.02 | — | — |
| Mar 31, 2023 | 0.03 | — | — |
| Mar 17, 2023 | 0.01 | 0.00 | — |
| Nov 10, 2022 | 0.04 | 0.00 | — |
| Aug 10, 2022 | -0.02 | 0.00 | — |